Safety and feasibility of esophagectomy following combined immunotherapy and chemoradiotherapy for esophageal cancer.

ABSTRACT:

Objectives

We sought to determine the safety and feasibility of esophagectomy after neoadjuvant immunotherapy and chemoradiotherapy in clinical trial patients with locally advanced esophageal cancer.

Methods

We retrospectively identified patients who were treated with neoadjuvant immunotherapy and chemoradiotherapy (n = 25) or chemoradiotherapy alone (n = 143) at our institution between 2017 and 2020. The primary end point was risk of 30-day major complications (Clavien-Dindo classification system grade ≥ 3), which was assessed between groups using a multivariable log-binomial regression model to obtain adjusted relative risk ratios. Secondary end points were interval to surgery, 30-day readmission rate, and 30-day mortality.

Results

All included patients successfully

SUBMITTER: Sihag S 

PROVIDER: S-EPMC7889638 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature